Alterity Therapeutics share price logo

Alterity Therapeutics

NASDAQ: ATHE

$4.47

-0.10

(-2.19%)

as on

Alterity Therapeutics Stock Performance

as on August 26, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $4.40
    $4.55
    downward going graph

    1.57%

    Downside

    1.79%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $2.66
    $5.89
    downward going graph

    40.49%

    Downside

    31.82%

    Upside

    downward going graph

Alterity Therapeutics share price movements today

Previous Close
$4.57
Open
$4.41
Volume
89.8K
Market Cap
$86.8M
Day's Low - High
$4.40 - $4.55
52 Week Low - High
$2.66 - $5.89

Alterity Therapeutics Historical Returns

1 Month Return
-3.82 %
3 Month Return
+ 18.86 %
1 Year Return
-8.76 %
3 Year Return
+ 76.1 %
5 Year Return
-63.15 %

Alterity Therapeutics Stock Fundamentals & Key Indicators

Check Alterity Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$86.8M

EPS (TTM)

-0.96

Dividend Yield

0.00%

PE Ratio (TTM)

-6.52

Industry PE ratio

-5.415

PEG Ratio

-0.09356295825228193

Return On Equity TTM

-30.19%

Alterity Therapeutics Stock Valuation

Track how Alterity Therapeutics P/E has moved over time to understand its valuation trends.

Alterity Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-5.45x)

June 30, 2025

Today (-5.45x)

June 30, 2025

Industry (-5.42x)

June 30, 2025

Highest (-0.86x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: -5.45x

Alterity Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alterity Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$86.8M-63.15%-6.5296.82%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$25.3B-84.24%-7.98-12.57%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Alterity Therapeutics Stock including INR - Dollar returns

The Alterity Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Alterity Therapeutics investment value today

Current value as on today

₹92,725

Returns

-₹7,275

(-7.28%)

Returns from Alterity Therapeutics Stock

-₹14,857 (-14.86%)

Dollar Impact

₹7,582 (+7.58%)

Analyst Recommendation on Alterity Therapeutics Stock

Based on 4 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 4 analysts, 100% of analysts recommend a 'BUY' rating for Alterity Therapeutics. Average target price of $12.5

Indian Investors' Interest in Alterity Therapeutics Stock

Search interest for Alterity Therapeutics Stock has decreased by -66% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-66% versus previous 30 day period

Alterity Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Total Revenue
2
2
2
2
1
1
2
1
3
-
Gross Profit
2
2
2
2
1
1
2
1
3
0
Operating Income
-9
-10
-10
-10
-7
-4
-12
-7
-7
-12
EBITDA
-8
-8
-8
-10
-7
-8
-14
-7
-7
-12
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-8
-8
-8
-10
-7
-4
-14
-8
-4
-12
Income Tax Expense
-2
-2
-2
-2
-1
-1
-2
-1
0
-2
Net Income
-6
-6
-6
-8
-5
-6
-12
-7
-4
-9
Net Profit Margin
98.38%
98.66%
99.18%
97.90%
96.58%
96.11%
96.53%
96.04%
98.33%
0.00%

Alterity Therapeutics Annual Profit & Loss

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
0
0
0
-
4
5
3
4
5
Gross Profit
0
0
0
0
3
4
3
3
5
Operating Income
-6
-7
-12
-10
-15
-15
-14
-19
-14
EBITDA
-6
-11
-12
-13
-15
-17
-14
-19
-14
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-7
-8
-12
-10
-15
-12
-13
-19
-12
Income Tax Expense
0
0
0
0
-3
0
0
0
0
Net Income
-7
-8
-11
-10
-15
-12
-13
-19
-12
Net Profit Margin
83.89%
89.16%
72.64%
0.00%
91.70%
92.88%
92.72%
94.67%
97.66%

Alterity Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Net Income
-5
-6
-6
-8
-3
-4
-12
-7
-3
-9
Operating Cash Flow
-9
-8
0
-5
-10
-4
-8
-8
-2
-10
Investing Cash Flow
0
0
0
0
0
0
0
-
-7
7
Financing Cash Flow
36
0
0
0
0
0
8
0
25
18
Change in Cash
28
-4
2
-6
-25
-4
0
-4
15
16

Alterity Therapeutics Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-7
-8
-12
-10
-15
-12
-13
-19
-12
Operating Cash Flow
-5
-6
-13
-9
-17
-12
-20
-12
-11
Investing Cash Flow
0
0
0
0
0
0
0
0
-7
Financing Cash Flow
0
0
12
3
36
16
0
9
39
Change in Cash
-6
-6
0
-5
18
6
-19
-3
20

Mutual Funds that own Alterity Therapeutics Stock

Check out the Mutual Funds with significant holdings in Alterity Therapeutics.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.006358%
1155

Global Institutional Holdings in Alterity Therapeutics

Funds
Holdings
Twin Lakes Capital Management, LLC
0.77%
Advisor Group Holdings, Inc.
0%
GAMMA Investing LLC
0.01%
CoreCap Advisors, LLC
0%
UBS Group AG
0%

Insights on Alterity Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ATHE has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 802.96K → 3.83M (in $), with an average increase of 54.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 542.3% return, outperforming this stock by 553.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ATHE stock has moved down by -6.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -4.97M → -9.43M (in $), with an average decrease of 89.8% per quarter

About Alterity Therapeutics

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
OrganisationAlterity Therapeutics
Headquarters500 Collins Street, Melbourne, VIC, Australia, 3000
IndustryBiotechnology
CEODr. David A. Stamler M.D.
E-voting on sharesClick here to vote

Key Management of Alterity Therapeutics

Name

Title

Dr. David A. Stamler M.D.

CEO & Director

Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.

CFO & Company Secretary

Dr. Rudolph Emile Tanzi Ph.D.

Chief Scientific Advisor and Member of Research & Development Advisory Board

Dr. Steven D. Targum M.D.

Chief Medical Advisor

Dr. Robert Cherny

Head of Research

FAQs

What is Alterity Therapeutics share price today?

Alterity Therapeutics share price today is $4.47 as on at the close of the market. Alterity Therapeutics share today touched a day high of $4.55 and a low of $4.40.

What is the 52 week high and 52 week low for Alterity Therapeutics share?

Alterity Therapeutics share touched a 52 week high of $5.89 on and a 52 week low of $2.66 on . Alterity Therapeutics stock price today i.e. is closed at $4.47,which is 24.14% down from its 52 week high and 68.05% up from its 52 week low.

What is Alterity Therapeutics's market capitalisation today?

Alterity Therapeutics market capitalisation is $0.00T as on .

How to invest in Alterity Therapeutics Stock (ATHE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alterity Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alterity Therapeutics Shares that will get you 0.3356 shares as per Alterity Therapeutics share price of $4.47 per share as on August 26, 2026 at 8:45 am IST.

What is the minimum amount required to buy Alterity Therapeutics Stock (ATHE) from India?

Indian investors can start investing in Alterity Therapeutics (ATHE) shares with as little as ₹95.41 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.10 in Alterity Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Alterity Therapeutics share’s latest price of $4.47 as on August 26, 2026 at 8:45 am IST, you will get 2.2371 shares of Alterity Therapeutics. Learn more about fractional shares .

What are the returns that Alterity Therapeutics has given to Indian investors in the last 5 years?

Alterity Therapeutics stock has given -63.15% share price returns and 29.18% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?